INS and metabolic syndrome: Earlier investigations have established a robust correlation between circulating pipecolate levels and obesity, metabolic syndrome, serving as a predictive indicator for the likelihood of future T2D, hyperglycemia (HG), and increased insulin secretion during early insulin resistance (IR), with a diminished role in the manifestation of advanced IR or T2D [33,34].